12-week RCT found metformin's effects on insulin sensitivity and mitochondrial function differed by baseline insulin resistance status
A 12-week double-blind, placebo-controlled RCT in 148 non-diabetic subjects stratified by baseline insulin sensitivity tested whether metformin improves outcomes in insulin-resistant individuals but worsens them in insulin-sensitive individuals. The study assessed insulin sensitivity, glucose regulation, aging biomarkers, and mitochondrial function via skeletal muscle biopsy pre- and post-intervention.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Jul 2, 2026 · Discovered: Sep 15, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- 148
- Duration
- 3 months
- Population
- 148 subjects recruited from two sites (Oklahoma Medical Research Foundation and University of Wisconsin-Madison), free of type 2 diabetes, stratified to insulin sensitive or insulin resistant groups
- Primary outcome
- Insulin sensitivity
- Effect size
- —
- Significance
- Not reported
- Journal
- Oklahoma Medical Research Foundation
- Published
- Jul 2, 2026
Sources
Primary source
- Oklahoma Medical Research Foundation ↗Clinical trial
Source versions
Assessment history
9/23/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.